INAVA-ARNO complexes bridge mucosal barrier function with inflammatory signaling

  1. Phi H Luong
  2. Matija Hedl
  3. Jie Yan
  4. Tao Zuo
  5. Tian-Min Fu
  6. Xiaomo Jiang
  7. Jay R Thiagarajah
  8. Steen H Hansen
  9. Cammie F Lesser
  10. Hao Wu
  11. Clara Abraham
  12. Wayne I Lencer  Is a corresponding author
  1. Harvard Medical School, United States
  2. Yale University, United States
  3. Novartis Institutes for Biomedical Research, United States
  4. Massachusetts General Hospital, United States

Abstract

Homeostasis at mucosal surfaces requires cross-talk between the environment and barrier epithelial cells. Disruption of barrier function typifies mucosal disease. Here we elucidate a bifunctional role in coordinating this cross-talk for the inflammatory bowel disease risk-gene INAVA. Both activities require INAVA's DUF3338 domain (renamed CUPID). CUPID stably binds the cytohesin ARF-GEF ARNO to effect lateral membrane F-actin assembly underlying cell-cell junctions and barrier function. Unexpectedly, when bound to CUPID, ARNO affects F-actin dynamics in the absence of its canonical activity as a guanine nucleotide-exchange factor. Upon exposure to IL-1β, INAVA relocates to form cytosolic puncta, where CUPID amplifies TRAF6-dependent polyubiquitination and inflammatory signaling. In this case, ARNO binding to CUPID negatively-regulates polyubiquitination and the inflammatory response. INAVA and ARNO act similarly in primary human macrophages responding to IL-1β and NOD2 agonists. Thus, INAVA-CUPID exhibits dual functions, coordinated directly by ARNO, that bridge epithelial barrier function with extracellular signals and inflammation.

Data availability

All data analysed during this study are included in the manuscript. Source data have been provided for Figure 3 C-F.

Article and author information

Author details

  1. Phi H Luong

    Department of Pediatrics, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  2. Matija Hedl

    Department of Medicine, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
  3. Jie Yan

    Department of Medicine, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
  4. Tao Zuo

    Department of Pediatrics, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  5. Tian-Min Fu

    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  6. Xiaomo Jiang

    Novartis Institutes for Biomedical Research, Cambridge, United States
    Competing interests
    Xiaomo Jiang, is affiliated with Novartis. The author has no other competing interests to declare.
  7. Jay R Thiagarajah

    Department of Pediatrics, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  8. Steen H Hansen

    Department of Pediatrics, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  9. Cammie F Lesser

    Department of Medicine, Division of Infectious Diseases, Massachusetts General Hospital, Cambridge, United States
    Competing interests
    No competing interests declared.
  10. Hao Wu

    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  11. Clara Abraham

    Department of Medicine, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
  12. Wayne I Lencer

    Department of Pediatrics, Harvard Medical School, Boston, United States
    For correspondence
    Wayne.Lencer@childrens.harvard.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7346-2730

Funding

National Institutes of Health (T32HD007466)

  • Phi H Luong

Crohn's and Colitis Foundation of America (Career Development Award)

  • Phi H Luong

Boston Children's Hospital (Rubin-Wolpow Fellowship)

  • Phi H Luong

National Institutes of Health (DK099097)

  • Clara Abraham

National Institutes of Health (DK048106)

  • Wayne I Lencer

National Institutes of Health (DK084424)

  • Wayne I Lencer

National Institutes of Health (P30 DK034854)

  • Wayne I Lencer

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2018, Luong et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Download links

Share this article

https://doi.org/10.7554/eLife.38539

Further reading

    1. Biochemistry and Chemical Biology
    2. Computational and Systems Biology
    Shinichi Kawaguchi, Xin Xu ... Toshie Kai
    Research Article

    Protein–protein interactions are fundamental to understanding the molecular functions and regulation of proteins. Despite the availability of extensive databases, many interactions remain uncharacterized due to the labor-intensive nature of experimental validation. In this study, we utilized the AlphaFold2 program to predict interactions among proteins localized in the nuage, a germline-specific non-membrane organelle essential for piRNA biogenesis in Drosophila. We screened 20 nuage proteins for 1:1 interactions and predicted dimer structures. Among these, five represented novel interaction candidates. Three pairs, including Spn-E_Squ, were verified by co-immunoprecipitation. Disruption of the salt bridges at the Spn-E_Squ interface confirmed their functional importance, underscoring the predictive model’s accuracy. We extended our analysis to include interactions between three representative nuage components—Vas, Squ, and Tej—and approximately 430 oogenesis-related proteins. Co-immunoprecipitation verified interactions for three pairs: Mei-W68_Squ, CSN3_Squ, and Pka-C1_Tej. Furthermore, we screened the majority of Drosophila proteins (~12,000) for potential interaction with the Piwi protein, a central player in the piRNA pathway, identifying 164 pairs as potential binding partners. This in silico approach not only efficiently identifies potential interaction partners but also significantly bridges the gap by facilitating the integration of bioinformatics and experimental biology.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Yamato Niitani, Kohei Matsuzaki ... Michio Tomishige
    Research Article

    The two identical motor domains (heads) of dimeric kinesin-1 move in a hand-over-hand process along a microtubule, coordinating their ATPase cycles such that each ATP hydrolysis is tightly coupled to a step and enabling the motor to take many steps without dissociating. The neck linker, a structural element that connects the two heads, has been shown to be essential for head–head coordination; however, which kinetic step(s) in the chemomechanical cycle is ‘gated’ by the neck linker remains unresolved. Here, we employed pre-steady-state kinetics and single-molecule assays to investigate how the neck-linker conformation affects kinesin’s motility cycle. We show that the backward-pointing configuration of the neck linker in the front kinesin head confers higher affinity for microtubule, but does not change ATP binding and dissociation rates. In contrast, the forward-pointing configuration of the neck linker in the rear kinesin head decreases the ATP dissociation rate but has little effect on microtubule dissociation. In combination, these conformation-specific effects of the neck linker favor ATP hydrolysis and dissociation of the rear head prior to microtubule detachment of the front head, thereby providing a kinetic explanation for the coordinated walking mechanism of dimeric kinesin.